Focus: Amplo Biotechnology is a newly founded biotech company focused on developing treatments for congenital myasthenic syndromes, a rare neuromuscular disorder space. The company went public in 2023 despite being early-stage, signaling significant investor confidence in its therapeutic area.
Profile data last refreshed 2h ago · AI intelligence enriched 2mo ago
Stable — net +1 jobs in 30d
1 added, 0 removed. Backfill posture.
High-risk, high-reward opportunity best suited for early-career scientists or business professionals willing to build from the ground up in an unvalidated clinical program.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Amplo Biotechnology
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Amplo Biotechnology's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo